TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer.

It is developing TSC-100 and TSC-101 that is in Phase I of clinical trial for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-204 that is in Phase I for the treatment of solid tumors.

The company also developing TSC-200, TSC-201, TSC-202, TSC-203, and TSC-205 for the treatment of solid tumors.

In addition, it engages in the developing vaccines for infectious diseases, such as SARS-CoV-2. The company has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer; and a collaboration agreement with Amgen to identify novel targets in Crohn's disease.

TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.